Continuous Glucose Monitoring in Inpatients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-10-31

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to contribute to current research regarding the feasibility and accuracy of CGM in the hospital setting for both the medical and cardiovascular intensive care (ICU) patient populations.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Accuracy, Feasibility and Acceptance of Continuous Glucose Monitoring in Critically Ill Patients

NCT02296372

Glucose Metabolism Disorders Diabetic Blood Glucose Monitoring Critical Illness

COMPLETED NA

Evaluation of Continuous Glucose Monitoring in Patients With ACS and Type 2 Diabetes in ICU

NCT04822740

Acute Coronary Syndrome Type 2 Diabetes

TERMINATED NA

A Comparative Study to Evaluate the Accuracy and Safety of the GlySure Continuous Intravascular Glucose Monitoring System Versus Intermittent Blood Glucose Monitoring

NCT01942902

Continuous Glucose Measurement

COMPLETED NA

Optimization of Glycemic Control in the Hospital and Critical Care Setting

NCT04015388

Hyperglycemia Diabetes Mellitus

COMPLETED

Admission Glucose ICU Study

NCT00569322

Hyperglycemia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The use of continuous glucose monitors (CGM) in the outpatient setting has dramatically increased as these devices continue to improve in both ease of use, accessibility, and accuracy. Federal Drug Administration (FDA) clearance of certain devices has now been granted in both pregnancy and automated insulin delivery systems. As the world has embraced the safety and efficacy of continuous glucose monitors in the outpatient setting, health systems have turned attention to the potential of utilizing these devices to improve glycemic control in the hospital setting. With the announcement of the FDA granting enforcement discretion regarding the use of CGM technology in the hospital setting during the COVID-19 pandemic, the result was an abundance of research evaluating the potential of CGM longevity in the hospital setting.

The Standards of Care in Diabetes: 2023 reported that "preliminary data suggests that CGM can significantly improve glycemic management and other hospital outcomes." Additionally, a systematic review of 32 studies evaluated the accuracy of CGM in the intensive care unit, with a consensus of moderate to good accuracy. CGM in the hospital setting could provide a valuable tool in reducing hypoglycemia, hyperglycemia, and increasing time spent in normoglycemia. Other potential benefits of CGM include a broader view of glucose patterns, capture of asymptomatic hypoglycemia, reduced length of stay, and decreased cost. The Diabetes Technology Society organized the Hospital Consensus Guideline Panel in 2020, with the final report including the recommendation for additional research on the accuracy, data management, and patient-centered outcomes of CGM use in the inpatient setting.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperglycemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Open-heart surgery inpatients

Patients having elective open-heart surgery including coronary artery bypass grafting (CABG), aortic valve repair/replacement (AVR), mitral valve repair/replacement (MVR), or any combination of those will have a CGM monitor placed within one hour of admission for up to 7 days or upon discharge.

CGM monitor

Intervention Type DEVICE

blood glucose sensor used to monitor interstitial glucose

General medical inpatients

Medical inpatients who have a Glucommander order for management of hyperglycemia will have a CGM monitor placed within 24 hours of admission for up to 7 days or upon discharge.

CGM monitor

Intervention Type DEVICE

blood glucose sensor used to monitor interstitial glucose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CGM monitor

blood glucose sensor used to monitor interstitial glucose

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Libre 3 Freestyle Continuous Glucose Monitor

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Admitted patients 18 years of age or older
* Glucose management per Glucommander and/or receiving POC blood glucose testing
* Patients admitted to Medical 6 or elective or urgent open-heart surgery patients admitted to the Cardiovascular Intensive Care Unit (CVICU)

Exclusion Criteria

* Patients less than 18 years of age
* Pregnant or currently breastfeeding
* Prisoners
* Patients unable to consent in English.
* Patients with a preexisting insulin pump on admission
* Active skin infection at the insertion site(s)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No